Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 127, Issue 12, Pages 4488-4497Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI90699
Keywords
-
Categories
Funding
- NIH [1K08HD075830-01A1, U01 AA022489, R21AA023574, R01 DK113592]
- German Research Foundation (DFG) [WR173/2-1, SFB/TRR 57]
- Intramural Research Program of the NIH, NIAID
- Intramural Research Program of the NIH, NIAMS
Ask authors/readers for more resources
The NLRP3 inflammasome is a protein complex responsible for caspase-1-dependent maturation of the proinflammatory cytokines IL-1 beta and IL-18. Gain-of-function missense mutations in NLRP3 cause the disease spectrum known as the cryopyrin-associated periodic syndromes (CAPS). In this study, we generated Nlrp3-knockin mice on various KO backgrounds including Il1b/Il18-, caspase-1-, caspase-11-(Casp1/11-), and Tnf-deficient strains. The Nlrp3(L351P) Il1b(-/-) Il18(-/-) mutant mice survived and grew normally until adulthood and, at 6 months of age, exhibited marked splenomegaly and leukophilia. Injection of these mice with low-dose LPS resulted in elevated serum TNF levels compared with Nlrp3(L351P) Casp1/11(-/-) mice and Il1b(-/-) Il18(-/-) littermates. Treatment of Nlrp3(A350V) mice with the TNF inhibitor etanercept resulted in all pups surviving to adulthood, with normal body and spleen/body weight ratios. Nlrp3(A350V) Tnf(-/-) mice showed a similar phenotypic rescue, with marked reductions in serum IL-1 beta and IL-18, reduced myeloid inflammatory infiltrate in the skin and spleen, and substantial decreases in splenic mRNA expression of both inflammasome components (Nlrp3, Pycard, pro-Casp1) and pro-cytokines (Il1b, Il18). Likewise, we observed a reduction in the expression of both pro-Casp1 and pro-Il1b in cultured Nlrp3(A350V) Tnf(-/-) BM-derived DCs. Our data show that TNF is an important transcriptional regulator of NLRP3 inflammasome components in murine inflammasomopathies. Moreover, these results may have therapeutic implications for CAPS patients with partial responses to IL-1-targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available